Choices for Induction of Pluripotency: Recent Developments in Human Induced Pluripotent Stem Cell Reprogramming Strategies by Brouwer, M. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/167649
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
Choices for Induction of Pluripotency: Recent Developments
in Human Induced Pluripotent Stem Cell Reprogramming
Strategies
Marinka Brouwer1 & Huiqing Zhou2,4 & Nael Nadif Kasri1,2,3
Published online: 1 October 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract The ability to generate human induced pluripotent
stem cells (iPSCs) from somatic cells provides tremendous
promises for regenerative medicine and its use has widely
increased over recent years. However, reprogramming effi-
ciencies remain low and chromosomal instability and tumor-
igenic potential are concerns in the use of iPSCs, especially in
clinical settings. Therefore, reprogramming methods have
been under development to generate safer iPSCs with higher
efficiency and better quality. Developments have mainly fo-
cused on the somatic cell source, the cocktail of
reprogramming factors, the delivery method used to introduce
reprogramming factors and culture conditions to maintain the
generated iPSCs. This review discusses the developments on
these topics and briefly discusses pros and cons of iPSCs in
comparison with human embryonic stem cells generated from
somatic cell nuclear transfer.
Keywords Human induced pluripotent stem cells .
Reprogramming
Introduction
Human embryonic stem cell (hESC) research has provided
valuable information on human development by the ability
to differentiate pluripotent hESCs into any human specific cell
type [1–3]. This ability is especially advantageous to acquire
human cells that are difficult to obtain (e.g., brain or cardiac
tissue). However, research using hESCs has been limited due
to strict ethical legislations [4–6]. In the last decade, several
reprogramming techniques that generate human pluripotent
stem cells from differentiated somatic cells were developed
successfully [7–10]. These techniques circumvent the ethical
legislations on hESCs.
The first reports of reprogramming somatic cells to
pluripotent stem cells were from Yamanaka and col-
leagues, in which they showed that introducing a set
of defined reprogramming factors (e.g., Oct4, Klf4,
Sox2 and c-Myc, (OSKM factors)) into the somatic
cells was sufficient to generate induced pluripotent stem
cells (iPSCs) [7, 11]. Since then, iPSC research has
attracted a lot of attention and has grown rapidly. The
iPSCs provide promises in basic research and regenera-
tive medicine, and can be used in a wide range of
applications including cell-based therapies, drug screen-
ing and disease model l ing. However, induced
reprogramming strategies of initial studies were ineffi-
cient (~0,01–0,02 %) [7, 8, 12] and the overexpression
of oncogenes such as c-Myc and Klf4 raises safety is-
sues. Furthermore, the virus based delivery methods re-
sul t in genomic integrat ion and expression of
transgenes, thereby limiting its application for clinical
purpose due to risk of insertional mutagenesis. In addi-
tion, although human iPSCs share many similar features
to human ESCs, epigenetic characteristics are distinct in
iPSCs. Therefore, numerous protocols have been
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developed to improve the induced reprogramming tech-
nique [13, 14]. The variables in these protocols include
the choice of the somatic cell source, reprogramming
factors, delivery method and culturing conditions. Fur-
thermore, somatic cell nuclear transfer has recently been
successfully performed to generate human ESCs (NT-
ESC) and provides an alternative method to confer hu-
man somatic cells to pluripotency.
In this review, the recent developments in strategies
for the generation of iPSCs will be discussed (Fig. 1).
The review will first briefly discuss the characterization
of human iPSCs, and subsequently focus on the vari-
ables that influence iPSC quality and reprogramming
efficiencies including cell source, reprogramming fac-
tors, delivery methods and culturing conditions. Further-
more, the comparison of generating human iPSCs and
human NT-ESCs will briefly be discussed. Given the
topic of this review concerning the use of human mate-
rials for research and therapy, studies using human de-
rived iPSCs will be the focus unless stated otherwise.
Characterization of iPSCs
As iPSC reprogramming efficiencies are low and the quality of
the generated iPSCs is influenced by several factors, it is impor-
tant to carefully characterize the iPSCs after reprogramming.
Different methods have been used to characterize iPSCs
(Fig. 2). The characteristic morphology of iPSCs is often used
as a first indication of iPSC formation. iPSCs can be observed as
small cells with large nucleus/cytoplasm ratios that form com-
pact colonies which are defined by clear borders. In addition to
cell morphology, many cellular and molecular methods are
used. One of these methods includes the assessment of the pres-
ence of pluripotency marker proteins (e.g., Oct4, Nanog,
SSEA3, SSEA4, TRA-1-60 and TRA-1-81), which are
expressed in pluripotent stem cells [15]. Since these markers
are not necessarily specific to pluripotent stem cells, the expres-
sion of multiple of the markers should be assessed in combina-
tion to determine the presence of pluripotent stem cells. Alkaline
phosphatase assays can also be used to mark iPSCs. This meth-
od uses the high enzymatic activity of phosphatases in pluripo-
tent stem cells to generate a fluorescent signal and can be used as
a live marker for iPSCs [16]. In addition to these methods using
morphological characteristics and cell specific markers, func-
tional evaluation of the generated iPSCs can be performed by
assessing the differentiation potential of the iPSCs. iPSCs
should be able to terminally differentiate into cells of all three
germ layers which can be evaluated through in vivo teratoma
formation assays or in vitro differentiation through embryoid
body (EB) formation into cells of the three germ layers. Further-
more, since reprogramming influences the genetic and epigenet-
ic make-up of the cells, iPSCs should be carefully characterized
for genetic aberrations and epigenetic analyses such as gene
expression and DNAmethylation profiles. Karyotyping is com-
monly used to evaluate genetic abnormalities in iPSCs.
Fig. 1 Overview of parameters influencing the reprogramming process.
Depending on the purpose of the iPSCs (cell therapy or research), choices
concerning the somatic cell type, reprogramming factors, delivery
method and culturing conditions have to be made. With each of these
aspects, we suggest to make choices on the indicated topics, depending on
their ranked priority for the given iPSC purpose. Overall, when using
iPSCs for cell therapy, safety should be the primary concern when
making choices for the different reprogramming methods. When using
iPSCs for research purposes, we recommend to choose methods which
optimize the efficiency of the reprogramming process
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However, if transgenes are used for reprogramming, it is also
important to evaluate if the expression levels of the transgenes
are properly down regulated once the iPSCs are formed. For
evaluation of the epigenetic profile of the iPSCs, DNA methyl-
ation patterns can be assessed. Since DNAmethylation contrib-
utes to silencing of genes, it is important that the generated
iPSCs show DNA demethylation at key pluripotency genes
(e.g., Oct4, Nanog, Sox2), while genes specific to the donor cell
type become methylated and silenced. Finally, it is important to
note that the methods used to characterize iPSCs mentioned
above should be used in combination rather than alone.
Cell Source
When considering the cell source for reprogramming, so-
matic cells should preferentially be easily accessible, sus-
ceptible for reprogramming and the reprogramming process
should ideally be highly efficient. Many human somatic cell
types have been successfully reprogrammed. However,
reprogramming efficiencies and kinetics vary between so-
matic cell types. Keratinocytes for example showed a 100
times higher reprogramming efficiency (~0,8 %) and were
reprogrammed two times faster than skin fibroblasts under
the same conditions [12]. Furthermore, in mice it has been
shown that immature cells are more readily reprogrammed
than terminally differentiated cells [17]. The comparison of
reprogramming efficiencies and kinetics of somatic cell
types between different studies is however complex since
many of these studies are different in their choice of nuclear
factors, delivery method and culturing conditions. Given
the amount of human somatic cells types that have been
reprogrammed using different techniques leading to differ-
ent reprogramming efficiencies, an in-depth comparison on
this topic is beyond the scope of this review.
Apart from the different reprogramming efficiencies and
kinetics, the choice of the reprogramming factors seems also
to be dependent on the somatic cell types. The OSKM factors
(Oct4, Sox2, Klf4 and c-Myc) were the first set of
reprogramming factors that were found to be able to repro-
gram somatic cells into iPSCs. However, with the exploitation
of other somatic cell sources and the development of
reprogramming strategies, other sets of reprogramming fac-
tors were found to be capable of reprogramming somatic cells.
For example, skin fibroblasts can be reprogrammedwithout c-
Myc. This decreases the risk of tumorigenesis, which is ben-
eficial for therapeutic purposes, but exclusion of c-Myc also
decreases reprogramming efficiency (~0,0004 %) [18]. Fur-
thermore, some somatic cell types already endogenously ex-
press reprogramming factors necessary for reprogramming at
sufficiently high levels. Melanocytes for example express
Sox2 endogenously at high levels and ectopic Sox2 is there-
fore dispensable for reprogramming [19]. Even more, neural
stem cells only need the introduction of one additional factor
(Oct4) for successful reprogramming [20].
Other factors which may influence the choice of the somat-
ic cell type are the ability to store the cells for longer periods of
time and the accessibility of the somatic cell types. Since
obtaining human fibroblasts is an invasive procedure, search
for other cell sources more easily accessible has been per-
formed. Cells from urine samples and (cord) blood samples
for example are more easily obtained and have been success-
fully reprogrammed [21–25]. Cells from cord blood samples
have the advantage that they may contain less somatic muta-
tions compared to adult cells. Furthermore, (cord) blood cells
have recently been shown to be reprogrammable after cryo-
preservation [26]. This provides opportunities for therapeutic
use and personalized medicine since (cord) blood samples of
individuals can be stored in blood banks and used to repro-
gram to hIPSC when necessary.
Fig. 2 Overview of factors which
should be assessed to characterize
reprogrammed iPSCs. iPSCs can
be characterized on five different
aspects: morphology,
pluripotency markers,
differentiation potential,
epigenetic profile and genetic
profile. For each aspect factors are
indicated which are important to
assess the different aspects
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The choice of the somatic cell type also influences the
quality of the acquired iPSCs. Given the pluripotent state of
the reprogrammed cells, iPSCs derived from different somatic
cell types should all be capable of differentiating into cell
types of all three germ layers. However, iPSCs are known to
retain an epigenetic memory of the donor cell [27–31]. Most
studied epigenetic memories refer to DNA methylation and
gene expression pattern. Ohi et al. showed that silencing by
DNA methylation was inefficient for several genes (e.g.,
COMT, C9orf64 and TRIM4), which were expressed in the
donor cell types, but not in human ES cells [30]. In both
mouse and human models, iPSCs derived from different cell
types have distinguishable gene expression patterns, DNA
methylation signatures and differentiation potential [32, 33].
As a result of the epigenetic memory, iPSCs derived from
donor cells of different germ layers show a differentiation
preference towards cell types of the original germ layer [27,
28]. For example, iPSCs derived from blood cells more read-
ily differentiate to hematopoietic cells, while fibroblast-
derived iPSCs form more colonies when differentiating in
the osteogenic direction [34]. In another mouse iPSC study,
Hiler et al. developed a quantitativemethod to score the ability
of iPSCs to form 3-dimensional retinae, and reported that
iPSCs derived from rod photoreceptor cells produced more
differentiated retinae than ESCs and fibroblast-derived iPSCs
[35]. However the epigenetic memory seems to be a rather
transient phenomenon. Continuous passaging of the iPSCs
attenuates the differences between iPSCs and ESCs, in both
epigenetic signature, as well as differentiation potential [32,
33]. This suggests that iPSCs lose the characteristics inherited
from the parent cells over time.
So far, most human iPSCs have been derived from cell
types of mesodermal origin including fibroblasts [7, 36] and
other mesenchymal derived cells [37–39], several cell types
from the hematopoietic lineage [23–25], amniotic fluid cells
[40], adipose stem cells [41], dental pulp cells [42, 43] and
urinary cells [22]. (for a more detailed overview of human
somatic cell types reprogrammed so far, the reader is referred
to the following database intranet.cmrb.eu/reprogramming
[14]). For cells of ectodermal and endodermal origin only
few cell types have been reprogrammed including
keratinocytes [12, 44], neural progenitors [20, 45] and mela-
nocytes [19] for ectoderm and hepatocytes [46] and pancreatic
islet beta cells [28] for endoderm. Given the epigenetic mem-
ory of the donor cell type it may therefore be important to
choose a donor cell type with the same germ layer origin as
the cell type to which the iPSC’s will be differentiated.
Reprogramming Factors
Generating iPSCs requires the introduction of pluripotency
related factors into the somatic cell. Apart from the four
well-known transcription factors, Sox2, Klf4, Oct4, c-Myc
and the alternative combination described by the Thomson
group containing Sox2, Oct4, Lin28 and Nanog [8], factors
such as other transcription factors, small molecules,
microRNA’s (miR) and culturing conditions have been found
to increase reprogramming efficiency and iPSC quality
(Table 1). Most factors have been found to target main cell
signalling pathways including the TGFβ, PI3K, β-catenin,
cAMP and the MAPK/ERK pathways as well as apoptosis/
cell cycle related pathways. Furthermore, several factors that
are known to be involved in chromatin remodelling pathways
or in the hypoxia response pathway have also been reported to
influence reprogramming. In this section we will discuss the
influence of the different reprogramming factors on the
reprogramming process.
The transcription factors that have been used so far to re-
program human somatic cells have been found to play impor-
tant roles in maintenance of pluripotency and self-renewal by
acting through complex transcriptional networks [57, 90].
Nearly all of the transcription factors that have been used to
reprogram human somatic cells are part of a core pluripotency
circuitry. Within this circuitry, two distinct modules have been
suggested to regulate transcription [90]. One involves the
Oct4-module, which also includes Sox2, Nanog, Sall4 and
Utf1 while the other involves the cMyc-module. Though sug-
gested to be distinct, crosstalk between the different modules
exist. Klf4 [48] and GLIS1 [56] for example are thought to be
upstream regulators of both the Oct4- and cMyc-module.
Furthermore, although not functioning as transcription fac-
tors, Lin28 and non-coding RNA’s Let7 and lincRoR have
been found to be directly involved in the core transcriptional
pathway and increase reprogramming efficiency (~2-fold in-
crease compared to OSKM alone) [71, 77]. Lin28 is a RNA
binding protein and has been found to mediate translation of
Oct4 [91] as well as the inhibition of miR Let7, which is
known to promote expression of pro-differentiation genes
[77]. Additionally, lincRoR is a long non-coding RNA that
has been found to regulate expression of core transcriptional
factors [71, 72]. For a more detailed overview of the core
transcriptional network in human pluripotent stem cells the
reader is referred to the following database: www.StemSight.
org [92].
For the clinical application of iPSCs, it is desired to have
the reprogramming efficiency as high as possible. So far
reprogramming efficiencies with OSKM transcription factors
are rather low which is probably not yet optimal for clinical
use. Addition to or replacement of the OSKM factors with the
previously discussed factors involved in the core transcrip-
tional pathway have shown to reach similar or increased
reprogramming efficiency compared to when using the
OSKM factors alone. Recently, it was shown that sequential
introduction of the OSKM factors increased reprogramming
efficiency ~5-fold compared to simultaneous introduction
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Table 1 Reprogramming factors capable of reprogramming human cells
Reprogramming factors Function Affected pathway Effect on pluripotency References
Oct4 maintenance of pluripotency and
self-renewal
core transcriptional circuitry + [7, 47]
Sox2 maintenance of pluripotency and
self-renewal
core transcriptional circuitry + [7]
Klf4 maintenance of pluripotency and
self-renewal
core transcriptional circuitry + [48, 49]
c-Myc maintenance of pluripotency and
self-renewal
core transcriptional circuitry + [7]
Lin28 maintenance of pluripotency,
translational
enhancer, inhibits let7
core transcriptional circuitry + [8]
Nanog maintenance of pluripotency and
self-renewal
core transcriptional circuitry + [8]
Sall4 maintenance of pluripotency and
self-renewal
core transcriptional circuitry + [50, 51]
Utf1 maintenance of pluripotency core transcriptional circuitry + [52]
p53 induces senescence, tumor suppressor apoptosis/cell cycle − [52–54]
p21 induces senescence, tumor suppressor apoptosis/cell cycle − [53]
P16Ink4a induces senescence, tumor suppressor apoptosis/cell cycle − [53, 55]
GLIS1 activates multiple pro-pluripotency pathways core transcriptional circuitry;
Wnt/β-catenin; PI3k; TGFβ
+ [56]
L-Myc suppresses differentiation associated
genes
core transcriptional circuitry + [57]
TGFβ Facilitates EMT TGFβ + [58]
MDM2 p53 inhibitor apoptosis/cell cycle + [59]
REM2 p53 inhibitor apoptosis/cell cycle + [60]
Cyclin D1 Stimulates E2F/ G1-S cell cycle
transition
apoptosis/cell cycle + [60]
SV40 large T antigen inhibits p53 tumor suppression apoptosis/cell cycle + [54, 61]
DOT1L histone H3K79 methyltransferase Chromatin remodeling − [62]
Cx43 Promotes MET transition E-cadherin/β-catenin + [63]
MBD3 histone deacetylation, chromatin remodeling Chromatin remodeling − [64]
Sirt6 chromatin remodeling/ telomere maintenance Chromatin remodeling + [65]
TCL1a stimulates akt pathway PI3k + [66]
RARy Binds RAREoct, promotes
Oct4 expression
core transcriptional circuitry + [67]
SNAIL Promotes EMT transition core transcriptional circuitry/TGFβ + [68]
Lrh-1 Binds RAREoct, promotes
Oct4 expression
core transcriptional circuitry + [67]
RCOR2 Facilitates histone demethylation Chromatin remodeling + [69]
Non-coding RNA
miR367 inhibits EMT TGFβ + [70]
LincRNA-ROR regulates expression of core
transcriptional
factors
core transcriptional circuitry + [71, 72]
miR302 inhibits EMT/stimulates
oct4 expression
TGFβ; core transcriptional
circuitry; apoptosis
+ [70, 73, 74]
miR766 Inhibits Sirt6 Chromatin remodeling − [65]
miR200c inhibits EMT/TGFβ pathway TGFβ + [75]
miR369 inhibits EMT/TGFβ pathway TGFβ + [75]
miR372 inhibits EMT/TGFβ pathway TGFβ + [76]
Let7 regulates expression of core
transcriptional
factors and prodifferentiation genes
core transcriptional circuitry/TGFβ − [77, 78]
miR19a/b inhibits PTEN PI3k + [79]
Small molecules
58 Stem Cell Rev and Rep (2016) 12:54–72
[58]. Liu et al. showed that reprogramming is a dynamic pro-
cess where the OSKM factors influence both the epithelial to
mesenchymal transition (EMT) and the mesenchymal to epi-
thelial transition (MET) [58]. EMT and MET play important
roles in embryonic development and cancer progression and
involve up- or downregulation of genes specific to epithelial
or mesenchymal cells [93, 94]. Pluripotent stem cells more
closely resemble epithelial cells showing tight compact colo-
nies and the cells express the epithelial marker E-cadherin.
However, the fibroblasts which are widely applied for
reprogramming are of mesenchymal origin and express mes-
enchymal markers including N-cadherin and Slug [58, 95].
This indicates that the fibroblasts may have to undergo at least
a MET phase to reprogram into iPSCs. The role of MET in
iPSC reprogramming is further supported by the ~3-fold in-
crease in reprogramming efficiency after the addition of
Connexin43 to the reprogramming cocktail compared to
reprogramming with OSKM alone [63]. Connexin43 is
thought to mediate MET by regulation of the expression of
E-cadherin, a marker of MET. Interestingly, addition of the
EMT promoting factor TGFβ to the reprogramming cocktail
throughout the reprogramming process decreased
reprogramming efficiency, but addition of TGFβ during the
first 2 days of reprogramming increased the efficiency ~2-fold
[58]. Similarly, overexpression of the EMT promoting factor
SNAIL at ear ly reprogramming stage increased
reprogramming efficiencies. Furthermore, Unternaehrer et al.
showed that overexpression of SNAIL enhanced
reprogramming of mesenchymal fibroblasts as well as
epithelial keratinocytes, indicating that somatic cells of both
mesenchymal and epithelial origin may need to undergo an
EMT phase for reprogramming [68]. Therefore, these findings
indicate that reprogramming may consist of at least two
phases, an initial EMT phase followed by a MET phase
(Fig. 3). Liu et al. suggest that the mesenchymal fibroblasts
can reach a more optimal mesenchymal state during the EMT
phase, making the cells more susceptible for the following
MET phase, thereby increasing the reprogramming efficiency.
Further investigation of this dynamic EMT-MET process and
the role of different factors herein may therefore be used to
optimise the reprogramming mechanisms, thereby increasing
reprogramming efficiency.
Another set of factors that have been used to reprogram
human somatic cell types are involved in the apoptosis/cell
cycle pathway. Several of these proteins including p53 are
tumour suppressors; they inhibit growth and promote senes-
cence, functions that are undesirable for the reprogramming
process. Targeting these type of proteins with shRNA’s during
reprogramming have shown to increase reprogramming effi-
ciency (between ~2- and 10-fold increase compared to OSKM
alone) [52, 53, 55]. However, given the risk of off-targets
effects, the use of shRNA’s may not be a useful technique in
a clinical setting. Therefore, other ways of inhibiting the apo-
ptosis pathway have been investigated. Overexpression of
proteins that are known to inhibit p53 (such as MDM2,
SV40 large T antigen and REM2) have been shown to in-
crease reprogramming efficiency as well (between ~1.5- and
23-fold increase compared to OSKM alone) [54, 59–61].
Table 1 (continued)
Reprogramming factors Function Affected pathway Effect on pluripotency References
Vitamin C alleviates cell senescence/antioxidant Hypoxia response + [80]
Valproic acid inhibits histone deacetylases Chromatin remodeling + [81]
CHIR99021 GSK3-inhibitor PI3k; Wnt/β-catenin + [82]
Parnate lysine-specific demethylase 1 inhibitor Chromatin remodeling + [82]
SB431542 ALK5/TGFβ receptor inhibitor TGFβ + [83]
PD0325901 MEK inhibitor MAPK/ERK + [83]
BIX-01294 Methyltransferase G9a inhibitor Chromatin remodeling + [45]
Lithium GSK3-inhibitor PI3k; Wnt/β-catenin + [84]
Maxadilan downregulates Caspase3 and 9,
anti-apoptotic
apoptosis + [85]
8-Br-cAMP Protein kinase A activator cAMP + [86]
A-83-01 ALK5/TGFβ receptor inhibitor TGFβ + [87]
Tiazovivin promotes survival, ROCK inhibitor PI3k + [83]
Y-27632 promotes survival, ROCK inhibitor PI3k + [88]
EPZ004777 DOT1L inhibitor Chromatin remodeling + [62]
DAPT Inhibits Notch/ increases core transcription
factor expression/ inhibits p53 pathway
core transcriptional
circuitry/ apoptosis
+ [89]
Reprogramming factors include non-coding RNA’s and small molecules. Each factor has a specific function in one or more pathways and has to be
upregulated (+) or downregulated (−) to induce reprogramming
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Chromatin remodelling is an important step in the
reprogramming process. As discussed before, DNA methyla-
tion is important to silence genes specific to the somatic cell
type and incomplete silencing of these genes causes an epige-
netic memory of the donor cell in the reprogrammed iPSCs.
DOT1L [62], MBD3 [64], RCOR2 [69], Sirt6 and Sirt6-
inhibitor miR766 [65] are involved in chromatin remodelling
and have been shown to affect reprogramming efficiency
when overexpressed or inhibited. DOT1L is a histone
H3K79 methyltransferase, which activates genes upon meth-
ylation. Although seemingly contradicting, inhibition of
DOT1L increased reprogramming efficiency ~3-fold com-
pared to OSKM alone [62]. The authors suggest that DOT1L
inhibition during the initial phase of reprogramming facilitates
loss of H3K79Me2 on genes associated with the donor cell
type thereby stimulating repression of these genes and pro-
moting reprogramming. Sirt6 on the other hand is known to
deacetylate H3K9Ac and H3K56Ac thereby repressing gene
expression. Overexpression of Sirt6 resulted in increased
reprogramming efficiency (~2-fold compared to OSKM
alone), likely by facilitating repression of donor cell type spe-
cific genes [65]. Likewise, RNA interference of Sirt6-inhibitor
miR766 increased reprogramming efficiency (~1.5-fold com-
pared to OSKM alone) [65].
Although overexpression or inhibition of other factors
in addition to (a subset of) the OSKM factors can increase
reprogramming, the overall efficiency remains low and is
considered a stochastic process. Rais et al. argued that
inhibition of MBD3, a member of the MBD3/NuRD com-
plex that represses gene activity by deacetylation, repro-
grams donor cells types into iPSCs in a deterministic fash-
ion rather than stochastic [64]. The OSKM factors them-
selves are thought to recruit the MBD3/NuRD complex to
the downstream target genes of the OSKM factors thereby
inhibiting their activity. Rais et al. found that inhibition of
MBD3 in addition to overexpression of the OSKM factors
yielded a reprogramming efficiency of nearly 100 %.
However, a recent report showed contradicting evidence
tha t MBD3/NuRD complex is requi red for the
reprogramming of mouse somatic cells [96]. Although
chromatin remodelers can increase the reprogramming ef-
ficiency, their use in reprogramming should be considered
with care, since they do not target specific genes, but
rather affect the entire genome. They may therefore cause
yet unknown and perhaps undesired side-effects due to
off-target chromatin remodelling.
As mentioned before, non-coding RNA’s can be used to
increase reprogramming eff ic iency. Most of the
microRNA’s used to increase reprogramming efficiency in-
hibit the TGFβ pathway, thereby inhibiting EMT [70, 73,
75, 76]. miR302 alone or combinations of microRNA’s
(miR302/miR367 [70] and miR302/miR200c/miR369
[75]) have been shown to be very potent in reprogramming
as they can fully replace the original OSKM transcription
factors, obtain a similar [75] or higher [70] reprogramming
efficiency (~2-fold increase) compared to OSKM and do not
require addition of other factors for reprogramming. All
combinations involve miR302, which has been shown to
stimulate the expression of Oct4/ Sox2 and Nanog as well
as inhibiting several factors that stimulate DNAmethylation
[73] and stimulating tumour suppressor related pathways
[74]. MicroRNA’s have the advantage of specifically
targeting multiple pathways and as seen for miR302 may
therefore reduce the amount of factors to be introduced to
induce pluripotency.
F ina l l y, t he use o f sma l l mo lecu l e s du r ing
reprogramming has also been shown to significantly im-
prove reprogramming efficiency and iPSC quality. The
small molecules that have been used to improve
reprogramming of human somatic cells target several dif-
ferent signalling pathways and affect chromatin remodel-
ling, which is extensively reviewed by Federation et al.
[97]. Unlike the other factors described previously, small
molecules do not require any additional delivery methods
to introduce them into the cells. This makes the
reprogramming process less labour intensive and enables
strict control of exposure of cells to the factors. However,
although the small molecules have a relatively high spec-
ificity for their targets, non-specific effect may cause cel-
lular toxicity. Development of highly specific small mol-
ecules may therefore decrease this toxicity and further
improve reprogramming efficiency. Recently, a cocktail
of small molecules alone have shown to be able to repro-
gram mouse embryonic fibroblasts with a comparable
Fig. 3 Sequential introduction of the OSKM factors induces EMT-MET
dependent reprogramming. Upon sequential introduction of OSKM (in
the order OK, M, S), somatic cells undergo an initial EMT phase where
mesenchymal genes including Slug, SNAIL and N-Cadherin are
upregulated. Once the cells reach an optimal mesenchymal state after
EMT they undergo MET by downregulating the mesenchymal genes
and upregulating epithelial genes including EpCAM, Ocln an E-Cadherin
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efficiency as when using transcription factors [98]. How-
ever, it is not yet established if reprogramming using
small molecules alone can also be achieved for human
cells.
In summary, the choice of the reprogramming factors is
dependent on many factors. First, the choice of the somatic
cell type may affect the choice of the reprogramming factors
used. Some somatic cell types exhibit a sufficiently high en-
dogenous expression of reprogramming factors that exoge-
nous introduction is unnecessary (e.g., Sox2 expression in
melanocytes [19]). Apart from this, the choice of the nuclear
factors also depends on the purpose of the acquired iPSC’s.
Several factors are oncogenic and may form a risk when ge-
nomic integration based delivery methods are used, which is
undesired for clinical purposes but is not necessarily problem-
atic for disease modelling, for example. In addition, the choice
of nuclear factors affects the efficiency of reprogramming. As
mentioned before, the reprogramming efficiency decreases
when fibroblasts are reprogrammed with only Sox2, Klf4
and Oct4 when compared to the addition of the oncogene c-
Myc to the reprogramming cocktail [18]. MicroRNA’s have
been shown to be able to fully replace nuclear factors and may
provide a more effective way of reprogramming than tradi-
tional nuclear factor reprogramming. Furthermore, small mol-
ecules can effectively increase reprogramming efficiency or
replace several nuclear factors. So far, reprogramming using
small molecules alone has only been established for mouse
cells [98]. However if this method is also effective on human
cells, it may provide a method for reprogramming iPSCs for
clinical purpose.
Delivery Method
In addition to the choice of the somatic cell type and the
reprogramming factors, it is important to select proper delivery
methods for the reprogramming factors to enter the cells. The
choice of the delivery method is strongly dependent on the
choice of the reprogramming factors. Small molecules for ex-
ample have the major advantage that they do not require any
additional delivery method. The other factors can be introduced
into the somatic cells as DNA, RNA or proteins. DNA can be
delivered into the cells using a variety of methods including
viruses [7, 99, 100], transposons [101, 102], bacteriophages
[103] and episomal vectors [104, 105] (Table 2). RNA can be
delivered using viruses [113] or directly as RNA molecules
[108] and proteins can also be directly introduced into the cells
[112] (Table 2). In this section we will discuss the different
delivery methods used to reprogram somatic cells and how this
affects reprogramming efficiency and quality.
Retroviruses provide a relatively easy and efficient way of
introducing factors into the somatic cells. However, retrovi-
ruses randomly integrate into the hosts’ genome and may
therefore lead to insertional mutagenesis in the obtained
iPSCs. Furthermore, the use of re t roviruses for
reprogramming is dependent on the choice of the somatic cell
type. Retroviruses require cell division to integrate in the ge-
nome. A slow-dividing somatic cell type will therefore reduce
reprogramming efficiency compared to fast-dividing cell
types. Furthermore, different subtypes of retroviruses have
been used for reprogramming and these subtypes do not infect
all types of cells with the same efficiencies [12, 115]. It is
therefore important to choose a subtype of retroviruses that
is capable of efficient infection of the chosen somatic cell type.
It is also important that once the iPSCs are formed, the inte-
grated transgenes will be silenced. The transgenes delivered
by retroviruses will be silenced over time, but silencing is not
always efficient and some transgenes may not be silenced at
all [116]. Furthermore, the transgenes that are efficiently si-
lenced will remain in the genome and may be reactivated later
on [115, 116].
Initially, several different retroviruses needed to be gener-
ated, each containing only one reprogramming factor [7]. This
method leads to multiple integration sites thereby increasing
the risk of insertional mutagenesis. Furthermore, the site of
integration is uncontrollable and all factors need to be
expressed to induce reprogramming. To overcome these prob-
lems, poly-cistronic lentiviruses were developed that contain
all reprogramming factors in one vector [117]. In these virus-
es, the reprogramming factors are driven by a single promoter
and separated by self-cleaving 2A peptide sequences. This
significantly reduces the amount of integration sites in the
somatic cells and provides a safer method of generating iPSC.
Unlike retroviruses, lentiviruses do not require cell division
to integrate into the hosts’ genome. Furthermore, lentiviruses
have the ability to infect a broader range of cell types than
retroviruses. The use of a lentivirus is therefore less dependent
on the choice of the somatic cell type compared to the use of
retroviruses. Like retroviruses, lentiviruses integrate
transgenes in the hosts’ genome, which may have the disad-
vantages of insertional mutagenesis, inefficient silencing or
transgene reactivation as is seen with retroviruses. Addition-
ally, the effects of inefficient silencing and transgene reactiva-
tion can be overcome with the use of excisable poly-cistronic
lentiviral vectors [118, 119]. By flanking the transgene se-
quence with LoxP sites, transgenes can be successfully ex-
cised when exposed to Cre recombinase. However, using a
CreLoxP system increases the workload of reprogramming
due to additional cloning of LoxP sites and screening for
proper excision. Furthermore, excision using a CreLoxP sys-
tem leaves a scar in the genome, which still may result in
insertional mutagenesis.
Another way of controlling lentiviral transgene expression
is with the use of doxycycline inducible lentiviruses [99, 106].
In these viruses a doxycycline inducible promoter drives the
transgenes. This not only allows for temporal regulation of
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transgene expression, but also allows for generation of ‘sec-
ondary’ iPSCs. Since the inducible system is still in the hosts’
genome once IPSCs are generated and differentiated into sec-
ondary fibroblasts, the fibroblasts can then be reprogrammed
upon treatment with doxycycline into secondary iPSCs.
Reprogramming secondary fibroblasts into secondary iPSCs
therefore does not require reinfection with viruses. Further-
more, the population of iPSCs that are obtained are more
homogeneous than virus-infected iPSCs [99, 106] and can
be used to investigate the mechanisms of reprogramming
[120].
To circumvent the risks associated with insertional muta-
genesis integration-free human iPSCs have been generated
using several methods, including adenovirus, Sendai virus,
the piggyBac system, minicircle vector, episomal vectors, di-
rect protein delivery and synthesized mRNA (Table 2). One of
these methods uses replication-defective adenoviruses to de-
liver reprogramming factors into the cells [100]. Although this
overcomes the problem of insertional mutagenesis, since the
virus is not integrated in the genome it will be diluted over
time due to host cell division. Reprogramming using adeno-
viruses therefore requires multiple viral infections throughout
the reprogramming process [100]. Furthermore, the produc-
tion of adenoviruses is labour-intensive and reprogramming
efficiencies using adenoviruses are lower compared to lenti- or
retroviruses.
Apart from viruses, reprogramming genes can be delivered
into cells using several other methods. Two of these methods,
transposons and bacteriophages, depend on integration of the
transgenes into the genome. The PiggyBac (PB) transposon
was the first transposon system to be used to generate human
iPSCs [101]. In general, this method depends on a PB
transposase which cuts inverted terminal repeat sequences that
flank all the reprogramming transgenes separated by 2A se-
quences and pasts this into TTAA-sites in the hosts genome.
Similarly, the PB transposon containing the transgenes can be
cut out of the genome once reprogramming is established
using the PB transposase. Although excision is also possible
with the use of lentiviruses as discussed previously, excision
of PB transposons does not leave genetic scars and therefore
forms no risk for insertional mutagenesis. Furthermore, unlike
using viruses, PB transposons can be used for reprogramming
of any cell-type and they allow the generation of xeno-
free iPSCs.
Table 2 Delivery methods used to deliver reprogramming factors into human somatic cells. Delivery methods can be divided in integrating and non-
integrating methods
Delivery method Advantages Disadvantages References
Integrative Retrovirus Very efficient, widely applied Genomic integration,
cell type specificity,
requires cell division
[7, 12]
Lentivirus Very efficient, does not require
cell division, infects wide
range of cell types,
inducible/excisable
Genomic integration [99, 106]
Transposon Relatively efficient, xeno-free,
excisable
Genomic integration,
risk of reintegration
[101, 102]
Bacteriophage Integrates in intergenic regions Genomic integration [103]
Zinc finger
nucleases
Targeted integration, excisable Genomic integration [107]
Non-integrative mRNA No genomic integration,
relatively efficient
Needs multiple transfections,
triggers immune response
[108–111]
Episomal vector No genomic integration,
relatively easy
Very inefficient, requires
multiple transfections,
risk of genomic integration
[104]
Protein No genomic integration Very inefficient, requires
multiple transfections,
requires high levels of
proteins
[112]
Adenovirus No genomic integration Very inefficient, requires
multiple infections
[100]
Sendai virus No genomic integration, infects
wide range of cell types,
easily removable
Requires multiple viruses
containing one factor each
[113, 114]
Minicircle DNA No genomic integration,
relatively easy,
small constructs, xeno-free
Very inefficient, requires
multiple transfections
[105]
Each method has advantages and disadvantages for use in reprogramming
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There are also several draw-backs to the use of PB trans-
posons in reprogramming. First, there is a risk that the trans-
poson will integrate back into the genome. Furthermore, the
human genome contains endogenous PB transposon elements
[121, 122], which may respond to the PB transposase that is
introduced to excise the transgene transposon. Additionally, a
considerable amount of transposon integration sites are found
within transcription units [123]. Recently, the Sleeping Beauty
(SB) transposon was used to reprogram human cells [102,
124], which can overcome several issues of the PB transpo-
son. First, the SB transposon integrates less in transcription
units than PB transposons [123]. Also, there are no SB-like
elements found in the human genome and the SB transposase
can therefore not affect endogenous transposable elements.
Furthermore the SB100X transposase is more efficient than
the PB transposase. Nevertheless, the use of transposons in
general requires multiple rounds of excision, and therefore
remains a risk of reintegration and overall reprogramming
efficiencies are relatively low compared to the use of viruses.
So far, the described methods that depend on integration in
the genome form a risk due to possibility of integration into
transcriptional regions thereby disturbing endogenous gene
expression. Bacteriophages use an integrase enzyme to insert
their DNA into bacterial DNA by reactions of phage attach-
ment sites (attP) with bacterial attachment sites (attB). AttB-
like sites have also been described to be present in the human
genome. Most of these sites have intergenic locations, al-
though some are located in introns [103]. More recently, zinc
finger nucleases were designed that could be used to generate
as well as enable engineering of human iPSCs [107]. These
also integrate into the genome, but in contrast to randomly
integrating methods, genomic locations can be specifically
targeted for integration using zinc finger nucleases. Further-
more, combining this system with the CreLoxP system allows
for removal of the transgenes after reprogramming [107].
Apart from the methods described above, DNA encoding
the reprogramming factors can be introduced into the cells by
transient transfection of DNA molecules. Like adenoviruses,
this method does not depend on integration into the hosts’
genome. Furthermore, this technique is relatively easy to use
compared to the use of viruses for gene delivery. The DNA
can be transfected into the cells as plasmids [104, 125–127] or
as minicircle DNA [105, 128]. Minicircle DNA has the ad-
vantage over plasmids that they are small constructs that only
contain the eukaryotic genetic material. Since they do not
contain the bacterial backbone of the original plasmid, they
may be less immunogenic than plasmids. However,
reprogramming efficiencies using these minicircles are ex-
tremely low [128]. Furthermore, both plasmids and minicircle
DNA generally require multiple transfections during
reprogramming since their expression is only transient. Al-
though recently a minicircle vector was developed (CoMIP),
which was able to reprogram human somatic cells with only a
single transfection, the use of this vector did not markedly
increase reprogramming efficiencies [129]. Since transfection
efficiencies are also dependent on the somatic cell type [130],
this method may not be optimal in all reprogramming condi-
tions. Although considered a non-integrating method,
transgenes have been detected in the host genome upon trans-
fection with plasmids [126].
Currently, episomal reprogramming has emerged as one of
the preferred non-integrat ing methods. Episomal
reprogramming is based on the Epstein-Barr Nuclear
Antigen-1 (oriP-EBNA1) that has the ability to replicate in
synchrony with the host genome by attaching to the host chro-
matin and replicating with each cell cycle division. The oriP/
EBNA1 vector undergoes stable extrachromosomal replica-
tion only once per cell cycle, without integrating into the host
genome. This results in an extended presence within a host
cell without integration or modification of the host’s genome.
Similar to previous discussed non-integrating methods the ef-
ficiency for hiPS generation with episomal reprogramming
remains low [104, 131]. The efficiency has considerably been
improved (10–100 fold) by suppressing p53 and using non-
transforming L-Myc instead of c-Myc, during the
reprogramming process [57]. Important advantages of epi-
somal reprogramming are the rapid loss reprogramming
agents and the high reliability of hiPSC generation from fibro-
blast and blood samples [132, 133]. However, the use of the
p53 shRNA is problematic for therapeutic use [57].
To completely avoid DNA integration into the hosts’ ge-
nome during reprogramming, reprogramming methods intro-
ducing mRNA into cells rather than DNA have been devel-
oped. Sendai viruses have been used to successfully introduce
RNA reprogramming factors into somatic cells [113, 114].
The Sendai virus efficiently introduced negative-strand single
stranded RNA of reprogramming factors into the cells. Impor-
tantly, Sendai viruses can infect a wide range of somatic cell
types and is therefore less dependent on somatic cell type
choice compared to retroviruses. Furthermore, the viral parti-
cles can be removed by antibody-mediated negative selection
against surface protein HN on the virus [113]. Point mutations
in polymerase-related genes of the Sendai virus enabled con-
trollable temperature-sensitive Sendai viruses that could be
removed from the hosts by temperature increase [114]. How-
ever, these viruses only contain up to one of the
reprogramming factors each. Reprogramming with four fac-
tors would therefore require four different viruses, which may
cause differences in stoichiometry of factors between hiPSC
clones. Recently, a new type of temperature-sensitive Sendai
virus was developed (TS12KOS) which contains three
reprogramming factors (Klf4, Oct4 and Sox2), thereby reduc-
ing the number of different viruses necessary for
reprogramming. In combination with a temperature-sensitive
Sendai virus containing c-Myc, TS12KOS was shown to ef-
fectively and more efficiently induce reprogramming
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compared to the combination of four different Sendai viruses
containing only one reprogramming factor each [134]. An
efficient Sendai virus that contains all four reprogramming
factors (Klf4, Oct4, Sox2 and c-MYC) in one virus have also
been developed. This Sendai virus (SeVdp) was developed
from the temperature sensitive variant, but can be removed
from the hosts using siRNA. The SeVdp virus, containing
all four Yamanaka factors, have been shown to successfully
reprogram human dermal fibroblasts of patients with Fabry
disease. [135, 136]. Although SeV reprogramming is efficient,
reliable and footprint-free a major drawback for the
therapeutical use comes from the fact that SeV is currently
not available commercially as a cGMP-grade reagent for
reprogramming [131].
Apart from delivery by Sendai viruses, RNA’s can be di-
rectly delivered into somatic cells by transfection as synthetic
modified mRNA. These mRNA’s can be capped with a 5′
guanine cap to increase RNA half-life and translation efficien-
cy. However, a fraction of the synthetic RNA’s remains
uncapped and bears 5′triphosphates, which can induce innate
immune responses. To reduce this response, synthetic RNA’s
can be treated with phosphatase prior to transfection. Further-
more, substitution of ribonucleoside bases cytidine and uri-
dine for the modified ribonucleosides 5-methylcytidine and
speudouridine respectively significantly reduced the immune
response. Addition of interferon inhibitors to culturing media
helps to reduce immunogenicity [108]. Although these
methods have been used during reprogramming of cells on
feeder cells, more recently feeder- and xeno-free iPSCs
reprogrammed with modified mRNA’s have been established
[109].
Although the immune response upon reprogramming with
mRNA’s can be reduced, other implications limit the use of
RNA’s for reprogramming. RNA’s have short half lives,
reprogramming therefore requires frequent transfections dur-
ing the reprogramming process to sustain reprogramming fac-
tor expression levels in the cells. Electroporation of the RNA’s
is therefore not the most suitable method for transfection and
other transfection methods may not work as efficiently on
each cell type [109]. To reduce the transfection frequency
Yoshioka et al. developed a self-replicating positive-strand
RNA replicon based on the Venezualan equine encephalitis
(VEE) virus RNA replicon [110]. With this method, cells re-
quire only one transfection round and the replicons are lost
over passaging of the established iPSCs. Furthermore, this
replicon contains all reprogramming factors thereby retaining
reprogramming factor ratios. However, this method also in-
duced an immune response, which has to be counteracted by
interferon inhibitors [110].
Finally, reprogramming factors can be introduced directly
as proteins into the somatic cells [112]. Like direct delivery of
mRNA, direct delivery of reprogramming proteins requires
multiple transfections to gain sufficiently high intracellular
levels for reprogramming. Kim et al. produced the
reprogramming proteins in HEK293 cells and used their ex-
tracts to treat somatic cells. Since macromolecules have im-
plications with transmembrane transport, Kim et al. coupled a
cell-penetrating peptide (CPP) to the proteins to be delivered.
However, reprogramming efficiencies using cell extracts con-
taining the reprogramming proteins is very inefficient. Possi-
bly, purification of the proteins may increase reprogramming
efficiency.
Recently Schlaeger et al. systematically compared the most
widely used integration free methods such as Sendai-viral
(SeV), episomal (Epi) and mRNA transfection methods using
a number of criteria [131]. Although all methods resulted is
high-quality hIPSC cells there are differences at the level of
aneuploidy rates, reprogramming efficiency, reliability and
workload. In summary, the choice of the delivery method
depends on the purpose of the generated iPSCs and may also
depend on the choice of the somatic cell type. Although inte-
grating methods have generally higher reprogramming effi-
ciencies than non-integrating methods, use of iPSCs in clinical
settings will require non-integrating methods to obtain high
quality iPSCs. Reprogramming factors can be introduced into
cells as DNA, RNA or proteins. DNA-basedmethods are most
efficient although even non-integrating methods (episomal
vectors) may integrate into genomes to some extent. Further-
more, RNA-based methods are relatively efficient and do not
integrate in the genome, but they are also highly immunogen-
ic. Finally, protein-based methods are promising but yet ex-
tremely inefficient.
Culture Conditions
Manipulation of the culture environment of iPSCs has shown
to be able to improve reprogramming efficiencies and iPSC
quality as well. FGF2 and human LIF for example are known
to inhibit differentiation and enable long-term culture of hu-
man pluripotent stem cells [82, 137]. More recently, addition
of CCL2 to the cultures has been shown to induce a hypoxia
response in the cells and enhance expression of pluripotency
genes [138]. The hypoxia response has been previously relat-
ed to increased reprogramming efficiencies as well. Transient
hypoxia conditions during reprogramming have been shown
to increase reprogramming efficiency [42, 139]. Hypoxia dur-
ing early stage of reprogramming is thought to induce several
factors (HIF1a and HIF2a) that shifts oxidative metabolism of
somatic cells to the glycolitic metabolism of pluripotent cells
while hypoxia during later stages of reprogramming inhibits
the reprogramming process [140]. However, though increas-
ing the reprogramming efficiency, it should also be taken into
consideration that hypoxia also causes cellular toxicity.
Apart from addition of growth factors, iPSCs require spe-
cific culturing conditions for growth and maintenance, as is
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discussed in detail by Chen et al. [141]. In general, iPSCs can
be cultured in three ways: (1) colonies, (2) non-colony mono-
layers and (3) suspension cultures. The first two methods re-
quire a certain extracellular matrix for the cells to grow on,
while in suspension cultures cells can grow either with or
without a matrix. Feeder cells are the most commonly used
form of extracellular matrix for the growth andmaintenance of
iPSCs as colonies. However, these feeder cells are usually
xenobiotic (e.g., MEFs) and the composition of the com-
pounds, which the cells excrete, is not fully defined. For clin-
ical purpose it is important to culture the iPSCs under fully
defined conditions. Therefore, the use of other feeder-free ex-
tracellular matrices have been investigated such as Matrigel
[7, 8], but also both feeder- and xeno-free matrices such as
laminin [142, 143], vitronectin [144] or synthetic surfaces
[145].
Matrigel has been used to sustain non-colony monolayers
of iPSCs. These monolayers have been shown to increase cell
viability and cells can be grown on larger scale then when
using the colony-based method [146, 147]. Likewise, suspen-
sion cultures enable scalable production of iPSC. As men-
tioned before, iPSC cultures in suspension do not require ex-
tracellular matrices [148, 149]. However, as a result, the cells
are subject to shear force that may cause damage [150]. Ad-
dition of coated microcarriers as a substrate for the cells and
microencapsulation may reduce this shear force, but so far this
has only be used on hESC [151, 152].
Since culture media often contain xenobiotic or chemically
undefined substances, fully xeno-free, defined culture media
have been developed including Essential 8 (E8) medium,
TeSR2 medium and NutriStem XF/FF medium [144, 153].
Each of these different media have been successfully used to
culture human iPSCs on xeno-free matrices. For example, E8
medium can be used for both adherent cultures (using
vitronectin as xeno-free matrix) and cell aggregate suspension
cultures in spinner flasks [154]. Furthermore, adherent iPSC
colonies cultured in E8 medium can be easily passaged by
addition of EDTA after removing the medium [155]. EDTA
can be used to passage iPSC colonies as loose aggregates
similar to dispase. The advantage of EDTA is that it is a de-
fined chemical and does not show batch-to-batch variability
like enzymes such as dispase [155]. Recently, culture condi-
tions for resetting human ESCs to the naive state have been
reported [156, 157]. These studies provide opportunities for
obtaining human iPSCs at the ground-state pluripotency.
Taken together, once iPSCs are obtained, specific culturing
conditions are required for their maintenance and growth.
Apart from the addition of growth factors to the medium, the
conditions in which the iPSCs grow and the substrate they
grow on are important variables. The use of iPSCs in clinical
settings require cells to be cultured under fully defined xeno-
and feeder-free conditions and the culture method should al-
low for scalable production of iPSCs.
Comparison to Somatic Nuclear
Transfer-Derived-ESCs
Other techniques have been explored to reprogram somatic
cells into stem cells other than by introduction of
reprogramming factors into the cells. One of these techniques
is somatic cell nuclear transfer (SCNT), which is based on the
transfer of the nucleus of a somatic cell into an enucleated
oocyte. The cytoplasmic content of the oocyte is sufficient
to reprogram the transferred nucleus to a pluripotent state,
thereby generating ES-like cells. This technique was the first
to be used to clone animals, but human ES-like cells have only
recently been established with this technique [9, 10, 158].
Like for induced reprogramming, SCNT is an inefficient pro-
cess. In a recent study on generating ESCs from SCNT
(SCNT-ESCs), Ma et al. showed that DNA methylation and
transcriptome patterns of SCNT-ESCs more closely resemble
those of human ESCs than those of iPSCs, whereas iPSCs
retained residual DNA methylation patterns that are typical
of parental somatic cells [159]. A possible explanation for
the apparent closer resemblance of SCNT-ESCs compared to
iPSCs is the use of an oocyte to reprogram the DNA of the
somatic cell. The oocyte may contain all physiological levels
of factors necessary for reprogramming and therefore be more
efficient than the artificial iPSC reprogramming technique.
However, another recent report showed that SCNT-ESCs
and iPSCs have similar gene expression and DNA methyla-
tion profiles, as well as comparable levels of genomic aberra-
tions such as coding mutations and imprinted gene expression
defects [160]. Although further investigations are necessary to
resolve the differences in these studies, these findings suggest
that NT-ESCs and iPSCs have similar properties and applica-
tion potentials. In addition, the major disadvantage of gener-
ating SCNT-ESCs is that it is dependent on donation of oo-
cytes from young women, and the procedure is sophisticated.
Therefore, iPSCs may still be a preferred method to provide a
large number of pluripotent stem cells in most laboratories,
especially for disease modelling studies.
Future Directions
Although progress has been made towards the establishment
of safer and more efficient reprogramming techniques, there
are still several remaining limitations for the generation of
clinical grade iPSCs. One of the most important is the rate of
mutagenesis during the reprogramming process. First of all,
the choice of the somatic cell type influences the mutational
load of the iPSCs. Older cells and cells that are frequently
exposed to environmental factors such as UV light might have
a higher mutational load than younger cells, such as cord
blood cells. Since cord blood cells are easy to obtain and can
be banked, they may provide an efficient source for clinical
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iPSCs. Furthermore, although using non-integrating delivery
methods may reduce the risk of mutagenesis, several investi-
gations have identified de novo mutations during
reprogramming and culturing of iPSCs when reprogramming
with both integrating and non-integrating methods [161, 162].
These genetic alterations result in variation amongst generated
iPSCs. As discussed before, epigenetic modifications may al-
so contribute to iPSC variation due to retained epigenetic
memories of the starting cell type [163]. These variations
may implicate differentiations of iPSCs towards the desired
cell type. Low reprogramming efficiencies also remain an
important issue for somatic cell reprogramming. Although
RNA delivery may be a promising efficient non-integrating
method, its reprogramming success rate is low and lentiviral
delivery is therefore still amongst the most successful
reprogramming method [164]. Addition to or substitution of
the four Yamanaka factors have been shown to increase
reprogramming efficiencies although not dramatically. Fur-
thermore, several factors appear to be oncogenic and should
therefore be chosen with careful consideration.
In summary, several aspects of the above-discussed
reprogramming process should be taken into consider-
ation when generating iPSCs (Fig. 1). iPSCs for clinical
purposes will most likely have to be of higher quality
and have to meet more stringent requirements than
iPSCs for research purposes. Important choices will
h av e t o b e mad e conc e r n i ng t h e n e c e s s a r y
reprogramming efficiencies and safety issues regarding
the use of e.g., xenobiotic substances and integrated
transgenes (e.g., oncogenes). The three parameters that
influence the reprogramming process are the somatic
cell type, the reprogramming factors and the delivery
method. Epigenetic memory and the cell type’s suscep-
tibility for infection or transfection may influence the
choice of the somatic cell type. Furthermore, the endog-
enous expression levels of reprogramming factors in the
chosen cell type and the possible side effects of the
introduced factors (e.g., oncogenicity, off-target effects)
influence the choice of the reprogramming factors. The
state of the reprogramming factors (DNA, RNA, protein,
small molecules) and the need for high reprogramming
efficiencies or integration-free iPSCs will also affect the
choice of the delivery method. Finally, improving cul-
turing methods for maintenance of human iPSCs may
increase overall reprogramming efficiencies and iPSC
quality. Regardless the chosen methods, the generated
iPSCs will obtain mutational load that still raises several
safety issues which will have to be overcome before use
of iPSC in c l in i ca l se t t ings . Al though o the r
reprogramming methods such as SCNT may provide
good alternatives, induced reprogramming remains to
be the mostly commonly used and thoroughly character-
ized method. Taken together, it is recommended to
carefully select the appropriate methods for the genera-
tion of iPSCs depending on their purposes.
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